Privi Speciality Chemicals share price today

Privi Speciality Chemicals Ltd's share price was ₹3,274.70 at the close on 4 November 2026. It has been rising for 80 weeks. That is 0.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,670 and ₹3,695, and at that close it sat 59% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Privi Speciality Chemicals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.

Over the last 11 years the share price moved +1,409% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: profit up on a year earlier for 12 quarters in a row (every quarter we can compare), revenue up on a year earlier for 11 quarters in a row and highest quarterly profit in 16 quarters.

1. Profit up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter profit was ₹118 crore, +31.1% on a year earlier.

   Why: Profit rose because demand was strong at home and abroad, with rising use of scent ingredients and more buying from African customers.

   Next results: check whether the H2 state incentive money comes in.

   From the earnings call on 30 Oct 2026.

2. Revenue up on a year earlier for 11 quarters in a row

   In the September 2026 quarter revenue was ₹760 crore, +11.9% on a year earlier.

   Why: Revenue rose because demand was strong at home and abroad. More scent ingredients went into products, and African customers bought more.

   From the earnings call on 30 Oct 2026.

3. Highest quarterly profit in 16 quarters

   Profit of ₹118 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: Profit hit a record because the company spread its fixed costs over more sales and sold a better mix of products.

   Next results: check whether the profit margin holds with new products.

   From the earnings call on 30 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Privi Speciality Chemicals reported revenue of ₹760 crore, up 11.9% from ₹679 crore a year earlier, and a profit of ₹118 crore, up 31.1% from ₹90.0 crore.

Privi Speciality Chemicals results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Privi Speciality Chemicals' management discussed these results on a call held on 30 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Privi Speciality Chemicals closed at ₹3,274.70 on 4 November 2026, down 3.3% from ₹3,388.00 a year earlier (7 November 2025) and up 92.9% over five years. Its highest weekly close since March 2016 was ₹3,694.90 on 3 July 2026.

Privi Speciality Chemicals share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: ex-date for an interim dividend of ₹5 a share. 4 Nov 2026: Privi Speciality Chemicals closed at ₹3,274.70, up 2.1% on the week and down 8.3% on the month.

Earlier

• 30 Oct 2026: Privi Speciality Chemicals held its results call for July to September 2026. Management guided: 20% annual revenue growth maintained for FY27 with momentum to continue in coming years and next year around ₹3,750-4,000cr.
• Results for July to September 2026: Revenue up 11.9% and profit up 31.1% on a year earlier.
• Our read, 22 Aug 2026: India's leading aroma chemicals manufacturer expanding capacity from 48,000 MT to 54,000 MT and transitioning into high-margin specialty molecules amidst structural China-plus-one tailwinds, offset by execution friction from repeated capital spending commissioning delays.
• 31 Jul 2026: ex-date for a dividend of ₹10 a share.

Our read of the business

Latest quarter: Revenue up 19.1% on a year earlier to ₹666 Cr with 23% operating margin; Phase 1 Capital spending Completion Moved to September 2026.

Our read after the latest results, written 22 August 2026.

Privi Speciality Chemicals paid ₹15 a share in regular dividends in the 12 months to 5 November 2026 (2 payments), a yield of 0.46% at the ₹3,274.70 close on 4 November 2026. The last was an interim dividend of ₹5 a share, ex-date 4 November 2026.

Privi Speciality Chemicals dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Privi Speciality Chemicals Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 9 of its last 10 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 30 October 2026, Privi Speciality Chemicals' management guided: 20% annual revenue growth maintained for FY27 with momentum to continue in coming years and next year around ₹3,750-4,000cr.

“I am pleased to share that we have delivered our strongest-ever quarterly performance, notwithstanding very adverse global headwinds. We have achieved our highest-ever sales and profitability.”Mahesh Babani, on the call for July to September 2026

What management guided

• Operating margin to stay at current band including new products.
• Expanded block to run at almost 85-90% in Q4 on annual contracts with Q3 partial flow; Phase-2 complete by June for commercial sales September onward.
• Remaining capital spending ₹1,000 crore of ₹1,400 crore total; Phase-2 ₹1,000 crore plus Phase-3 ₹450-500cr plus Phase-1 ₹450 crore totalling ₹1,900 crore by 2030 toward ₹5,000 crore vision.
• Amalgamated units revenue ₹250-300cr at 80-85% of 6,000 MT base post approvals and merger by year-end from around ₹100 crore now.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 30 October 2026.

What is changing at Privi Speciality Chemicals, from the latest results and calls: operating leverage and continuous distillation efficiency, china-plus-one export market share gains and phase 1 capacity expansion to 54,000 mt.

• Operating Leverage and Continuous Distillation Efficiency. Fixed-cost absorption across ~90% capacity utilization and continuous processing drove FY26 operating profit up 42.1% on a year earlier with quarterly interest costs falling to ₹17 Cr. ⚠ estimate
• China-Plus-One Export Market Share Gains. An 18% tariff advantage over Chinese manufacturers and EcoVadis Platinum ESG certification position Privi to capture export demand across global blenders. ⚠ estimate
• Phase 1 Capacity Expansion to 54,000 MT. Phase 1 capital spending adds 6,000 MT (+12.5%) taking total capacity from 48,000 MT to 54,000 MT, scheduled for September 2026 completion to unlock FY27 volume ramp. ⚠ estimate
• High-Margin Specialty Molecules and Biomass Platform. New specialty chemistry platforms (Furfural-to-Maltol, Cyclafentanol) goal ₹1,000 Cr+ revenue at 27-28% margins with mechanical completion around mid-FY28. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown.

Our read after the latest results, written 22 August 2026.

A delay of Phase 1 capital spending commissioning beyond October to December 2026 or operating margin compression below 20.0% over two consecutive quarters caused by raw material cost pass-through failure.

The main risks

• Phase 1 Capital spending Fourth Completion Delay: Management has shifted Phase 1 capital spending commercialization across four consecutive calls (Dec 2025 → Apr 2026 → Jun 2026 → Sep 2026), creating execution drag on FY27 volume guidance. ✓ fact
• Raw Material (Alpha-Pinene / GTO) Price Volatility: Alpha-Pinene and Gum Turpentine Oil cost increases create gross margin risk if annual contract resets lag spot raw material inflation. ⚠ estimate
• Biotech and Enzymatic Chemistry Long Payback Horizon: Biomass demonstration plant (₹70-75 Cr capital spending) carries a 3-year commercialization path to reach economic parity with petrochemical synthesis. ✓ fact
• Group Merger Execution and Integration Timelines: NCLT approval for the merger of Privi Speciality Chemicals, Fine Sciences and Biotechnologies has slipped from FY26 to late FY27. ✓ fact

Our read after the latest results, written 22 August 2026.

When Privi Speciality Chemicals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Expanded-block utilization in Q4 on annual contracts - verify flagged high utilization delivers volume uplift.

Privi Speciality Chemicals is on one of our India lists: Small & mid cap stocks.

Privi Speciality Chemicals Ltd earned ₹118 Cr of net profit in the Sep 2026 quarter, +31.1% on the same quarter a year earlier. That is the 10th quarter in a row of profit growth. Full-year FY26 profit was ₹317 Cr. Over 9 years profit has grown 31.5% a year on average. That is 15.5% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹90.0 Cr.

For the full year, FY26 profit was ₹317 Cr (+71.4% on the year before).

Why profit moved: revenue changed +11.9% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +47.9% and revenue +17.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.

FY27-Q2. revenue ₹760 Cr and profit ₹118 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Privi Speciality Chemicals Ltd reported ₹760 Cr of revenue in the Sep 2026 quarter, +11.9% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 9 years it has grown 17.6% a year on average. The last full year, FY26, came in at ₹2,564 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,753 Cr.

FY26 revenue was ₹2,564 Cr, +22.0% on the year before.

Recent pace: the last four quarters grew +17.9% on average, against 17.6% a year over the longer run, so this year is growing at about the same pace as its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +17.5%, against +20.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +44.5%, against +64.3% a year (rolling over).

FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.

FY27-Q2. revenue ₹760 Cr and profit ₹118 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Privi Speciality Chemicals Ltd's operating margin was 26.0% in the Sep 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 10 years it has been between 12.0% and 25.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Privi's operating leverage mechanism is demonstrated by FY26 results where 21.7% revenue growth translated into 42.1% operating profit growth and 75.2% PAT growth. High asset utilization (~90%) across core aroma chemical distillation columns combined with engineering optimizations (steam conservation, yield maximization) maintained operating margins between 23% and 27% across the past four quarters. Concurrently, quarterly interest expense declined from ₹24 Cr in Jun 2025 to ₹17 Cr in Jun 2026, delivering financial leverage.

Why the margin moved: operating margin changed −0.6 percentage points on the year while gross margin changed −4.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

FY27-Q1. revenue ₹666 Cr and profit ₹83 Cr as reported.

FY27-Q2. revenue ₹760 Cr and profit ₹118 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Over the last 3 years, 198% of Privi Speciality Chemicals Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹550 Cr of operating cash against ₹317 Cr of profit. After ₹330 Cr of spending on assets, ₹220 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 198% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: the bigger use of cash is spending on new assets, at 1.9× depreciation over three years. The next section checks what that spending is building.

Privi Speciality Chemicals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 160 days in FY26, up from 155 days in FY21. It spent ₹765 Cr on assets over the last 3 years. Customers take 75 days to pay, and stock sits for 235 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,564 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly ₹1,124 Cr is tied up in the business at any time.

FY26: customers took 75 days to pay and stock sat for 235 days, about 7.7 months of sales sitting as stock, for a full cycle of 160 days, longer than FY21's 155.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 235 days. Customers pay about 75 days after that. Suppliers are paid at 150 days. Together that makes the 160-day cycle.

Spending on assets: ₹765 Cr over the last 3 years, against ₹399 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹314 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Privi Speciality Chemicals Ltd's P/E is 34.3×, near the low end of its own history: it has been lower only 32% of the time. Its usual P/E (the middle reading) is 42.9×, over 9.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.